What does this research mean for the field?

Magee equations provide a safe and cost-effective triage strategy for HR+/HER2- early breast cancer, achieving up to 99% negative predictive value for excluding high-risk disease and sparing up to 61% of costly OncotypeDX testing. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to validate the performance of the Magee equations as a triage tool for the OncotypeDX recurrence score in early breast cancer.

May 29, 2026

Validation of pathology-based triage for the 21-gene recurrence score: A meta-analysis and qualitative synthesis of the Magee equations.

Key Points

This research aims to validate the performance of the Magee equations as a triage tool for the OncotypeDX recurrence score in early breast cancer.
A systematic review identified 13 validation studies comparing Magee equations with OncotypeDX RS.
Studies included had sufficient data to create a 2X2 contingency table; neoadjuvant trials were excluded.
Meta-analysis pooled data and qualitative synthesis identified sources of discordance.
For RS >26, Magee <18 achieved pooled NPV of 0.96 (95% CI: 0.94-0.97) and TSR 61% (95% CI:51%-69%).
For RS >31, NPV increased to 0.99 (95% CI: 0.97-1.00) and TSR 52% (95% CI: 44%-59%).
Sensitivity for predicting RS <26 was 83% with specificity at 71% (AUC 0.81).

Abstract

1591 Background: The 21-gene OncotypeDX (ODX) recurrence score (RS) is the standard for chemotherapy decision-making in HR+/HER2- early breast cancer (EBC), but cost limits accessibility in resource-constrained settings. The Magee equations (MEs) use routine pathology features (Nottingham grade and IHC; ER/PR/HER2/Ki-67) to estimate RS. We performed a meta-analysis to validate MEs performance as a triage tool for ODX testing and a qualitative synthesis to identify sources of discordance, highlighting the transition toward objective digital pathology AI models. Methods: A systematic review identified validation studies comparing MEs with RS in HR+ EBC. Studies with sufficient data to construct a 2X2 contingency table were included; neoadjuvant trials were excluded. Primary outcomes were Negative Predictive Value (NPV) for identifying low-risk cases (RS 26, Magee 31, NPV increased to 0.99 (95% CI: 0.97-1.00) and TSR 52% (95% CI: 44%-59%). Pooled diagnostic performance for Magee 26 8 4153 0.96 (0.94-0.97) 61% (51%-69%) Magee 31 5 1243 0.99 (0.97-1.00) 52% (44%-59%)

KI fragen

Bookmark

Cite This Study

Susiriwatananont et al. (Wed,) studied this question.

synapsesocial.com/papers/6a192ed7fab5b468c4418084 https://doi.org/https://doi.org/10.1200/jco.2026.44.16_suppl.1591

KI fragen

Bookmark